The goal of the Yale Center for Genome Analysis (YCGA) is to rapidly and cost-effectively bring state-of the- art genomic technologies within reach of largest possible number of cancer investigators. YCGA occupies 7,000 ft^ of newly constructed, custom-designed laboratory space and is well equipped with several microarray (Affymetrix, lllumina, Sequenom and NimbleGen) and high throughput sequencing (10 lllumina hiiSeqs, one each of PacBio RS, MiSeq and Ion Torrent) platforms. Sequencing operation is supported by 1000 CPU/core cluster and 2 PB data storage. All aspects of sequence data generation, including sample collection, library preparation, sequence data and billing are tracked using WikiLIMS system which is an online, flexible, scalable and password-protected database. YCGA staff from microarray, sequencing and bioinformatics sections will provide an extremely expert and highly dedicated team that will ensure the success of research goals of cancer investigators. The YCGA provides >30 genomic services including: 1) gene expression and whole transcriptome analysis, 2) SNP genotyping and copy number variation, 3) whole-exome and whole-genome sequence analysis, 4) analysis of formalin-fixed paraffin embedded tissue, 5) methylation analysis, 6) miRNA analysis and discovery and 7) chromatin immunoprecipitation to study protein-DNA interactions. Together, the microarray and HT sequencing technologies of YCGA offer comprehensive support to study genetic events in cancer, which has the potential to aid in identification of genetic and biochemical causes of the disease, develop better diagnostic methods, and improve therapeutic outcomes and patient care. Strengths of this application include the extensive expertise, infrastructure, and instrumentation in the YCGA;the experience of PI in overseeing the recent U54-suported Yale Centre for Mendelian Disorder;a strong publication record and the experience of YCGA at providing state-of-the-art microarray, HT sequencing, biostatistical/bioinformatics and other technologies on a service charge basis to several Yale and non-Yale investigators. In addition to providing genomic services, the YCGA staff will consult as needed on experimental design, data interpretation, manuscript preparation, and grant application preparation, and will provide training for primary data analysis to YCC members. During FY 2012, 72 YCC investigators using YCGA Resource services accounted for 49% of the 20,148 provided services.

Public Health Relevance

The Yale Center for Genome Analysis provides cancer investigators a state-of-the-art centralized facility required for carrying out large-scale genomic analyses that would not otherwise be possible in their own laboratories. The genomic data generated at the YCGA is helping cancer scientists to better understand the genetic basis of cancer that will ultimately lead to new approaches for cancer treatment and prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755635
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$124,875
Indirect Cost
$49,875
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564

Showing the most recent 10 out of 675 publications